Sept 10 (Reuters) - Theratechnologies Inc TH.TO :
* THERATECHNOLOGIES TO DEVELOP TESAMORELIN FOR THE TREATMENT OF NASH IN THE GENERAL POPULATION
* THERATECHNOLOGIES INC - PHASE 3 PROTOCOL TO BE FILED IN Q4 2020; TRIAL EXPECTED TO BEGIN EARLY 2021
* THERATECHNOLOGIES INC - CLINICAL STUDY TO INCLUDE HIV COHORT